Phase 3 in Focus - Ampreloxetine, Theravance Biopharma

J Parkinsons Dis. 2021;11(2):391-393. doi: 10.3233/JPD-219004.

Authors

Kevin McFarthing¹, Neha Prakash², Tanya Simuni³

Affiliations

¹ Parkinson's Research Advocate, Oxford, UK.
² Parkinson and Movement Disorders Center, University of Connecticut School of Medicine, Farmington, CT, USA.
³ Parkinson's Disease and Movement Disorders Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

PMID: 33749621
DOI: 10.3233/JPD-219004

No abstract available

Publication types

Clinical Trial, Phase III
Multicenter Study

MeSH terms

Drug Evaluation
Humans
Parkinson Disease*
Phenyl Ethers / chemistry
Phenyl Ethers / pharmacology*
Piperidines / chemistry
Piperidines / pharmacology*

Substances

Phenyl Ethers
Piperidines
ampreloxetine